Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | MRTX-1133 |
Trade Name | |
Synonyms | MRTX1133|MRTX 1133 |
Drug Descriptions |
MRTX-1133 selectively inhibits KRAS G12D, which results in decreased downstream signaling and potentially leads to reduced tumor growth (PMID: 34889605). |
DrugClasses | KRAS G12D Inhibitor 9 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Afatinib + MRTX-1133 | Afatinib MRTX-1133 | 0 | 0 |
Alpelisib + MRTX-1133 | Alpelisib MRTX-1133 | 0 | 0 |
Canertinib + MRTX-1133 | Canertinib MRTX-1133 | 0 | 0 |
Cetuximab + MRTX-1133 | Cetuximab MRTX-1133 | 0 | 0 |
Erlotinib + MRTX-1133 | Erlotinib MRTX-1133 | 0 | 0 |
Lapatinib + MRTX-1133 | Lapatinib MRTX-1133 | 0 | 0 |
MRTX-1133 | MRTX-1133 | 5 | 1 |
MRTX-1133 + Neratinib | MRTX-1133 Neratinib | 0 | 0 |
MRTX-1133 + Trametinib | MRTX-1133 Trametinib | 0 | 0 |
MRTX-1133 + Ulixertinib | MRTX-1133 Ulixertinib | 0 | 0 |